Figure 3.
Effects of syringaresinol treatment on senescence. (A) Quantification of senescence by using SA-β-Galstaining for cells cultured from PD14 to PDL40 with or without 50μM syringaresinol. (B) Measurement of proliferative capacity of cells cultured with or without syringaresinol (50μM) was measured using BrdU incorporation. (C) Telomerase activities were measured in HUVECs at different PDLs with or without syringaresinol and the relative levels to the activity at PDL 14 were compared. (D-E) SA-β-Gal staining of HUVECs and quantifications of SA-β-Gal positive cells at PDL40 treated every 48 hours starting from PDL14 with 50μMsyringaresinol (SYR), 10mM Sirtinol, SIRT1 siRNA, and FOXO3 siRNA. All the results are either representatives or means ± S.E of at least three independent experiments. Significance was assessed by t-test. *P < 0.05.